AbbVie Inc., Redwood City, California, USA.
Takeda Pharmaceuticals International Co., Cambridge, Massachusetts, USA.
Clin Pharmacol Ther. 2018 Feb;103(2):152-159. doi: 10.1002/cpt.952.
We live in an era of precision therapeutics, value-based healthcare, patient-participatory research, and enhanced clinical trial transparency, with explosive increases in our ability to access and analyze multiscale biological and clinical data from diverse ecosystems. To discover and develop truly transformative medicines with a patient-centric sense of urgency, we will need to exploit data that lie far beyond the confines of laboratory-based experimental models and controlled clinical trials, dynamically maximizing the value of information in real-world data from clinical practice settings and even social media. This demands commitment to a culture that embraces Reverse Translation as a critical component of the practice of Translational Medicine in the discovery, development, regulation, and utilization of therapeutics.
我们生活在精准医疗、基于价值的医疗保健、患者参与式研究和增强临床试验透明度的时代，我们获取和分析来自不同生态系统的多尺度生物和临床数据的能力呈爆炸式增长。为了以一种以患者为中心的紧迫感发现和开发真正具有变革性的药物，我们将需要利用远远超出实验室基础实验模型和对照临床试验范围的数据，从临床实践环境甚至社交媒体中动态地最大化真实世界数据信息的价值。这需要致力于一种文化，将反向翻译作为发现、开发、监管和利用治疗药物的转化医学实践的关键组成部分。
